Catheter ablation treatment in patients with drug-refractory atrial fibrillation: A prospective,multi-centre, randomized, controlled study

Casa di Cura San Michele0 个研究点目标入组 137 人开始时间: 2015年10月19日最近更新: 2017年2月6日

适应症

试验速览

暂无简介。

•1. Aged between 18 and 80 years
•2. History of paroxysmal (1 or more episodes of AF a month in the last 12 months, each lasting more than 60 min but less than 7 days, with all episodes terminating spontaneously) or persistent (2 or more episodes of AF in the last 12 months , each lasting more than 7 days before being terminated medically) atrial fibrillation first diagnosed at least 6 months before enrollment
•3. Intolerant of antiarrhythmic drugs or in whom 2 or more antiarrhythmic drug regimens had failed

•1. Permanent atrial fibrillation (atrial fibrillation was the sole rhythm for the last 12 months)
•2. Atrial fibrillation secondary to a transient or correctable abnormality, including electrolyte imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy
•3. Persistence of atrial fibrillation episodes triggered by another uniform arrhythmia (i.e. atrial flutter or atrial tachycardia) despite previous supraventricular tachycardia ablation
•4. Intra-atrial thrombus, tumour, or other abnormality precluding catheter insertion
•5. Wolff–Parkinson–White syndrome
•6. Heart failure with NYHA class III or IV or left ventricular ejection fraction <35%
•7. Unstable angina or acute myocardial infarction within 3 months
•8. Cardiac revascularization or other cardiac surgery within 6 months or with prior atrial surgery
•9. Renal failure requiring dialysis, or hepatic failure
•10. An implanted device (pacemaker or cardioverter-defibrillator)
•11. Left atrial diameter >60 mm

发起方

Casa di Cura San Michele